SCHEMBL97780

SCHEMBL97780

NC(=O)CCSSCCC(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.56
LMNA P02545 5/20 0.43
CYP1A2 P05177 5/20 0.40
TDP1 Q9NUW8 3/20 0.38
KMT2A Q03164 3/20 0.38
HSD17B10 Q99714 2/20 0.38
THPO P40225 3/20 0.37
ALOX15 P16050 2/20 0.37
BLM P54132 2/20 0.37
PMP22 Q01453 2/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C19 P33261 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GMNN O75496 1/20 0.37
USP2 O75604 1/20 0.37
GLA P06280 1/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL180144 0.97 TSHR (0.53) TSHRLMNACYP1A2TDP1KMT2A
Hydrochloric Acid SCHEMBL1844352 0.97 TSHR (0.53) TSHRLMNACYP1A2TDP1KMT2A
SCHEMBL5067235 0.91 TSHR (0.48) TSHRLMNACYP1A2TDP1KMT2A
SCHEMBL163253 0.91 TSHR (0.72) TSHRLMNACYP1A2TDP1KMT2A
SCHEMBL14235175 0.89 TSHR (0.46) TSHRLMNACYP1A2TDP1KMT2A
SCHEMBL6548055 0.88 TSHR (0.43) TSHRLMNACYP1A2TDP1KMT2A
SCHEMBL19308751 0.87
SCHEMBL16358111 0.85
SCHEMBL3078846 0.84 TSHR (0.45) TSHRLMNACYP1A2TDP1KMT2A
SCHEMBL14042508 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122011511-A Nanometer clay composite reinforcing agent for rubber and preparation method thereof 宁波嘉和新材料科技有限公司 2026-05-12 CN claimed
US-12576163-B2 Fluorescent contrast agent with targeting function, and preparation method and use thereof PEKING UNIVERSITY THIRD HOSPITAL (CN) 2026-03-17 US claimed
EP-4689130-A2 METHODS AND COMPOSITIONS FOR ENHANCED EXPRESSION OF EXOGENOUS CASEINS IN TRANSGENIC PLANTS Mozza Foods Inc. (US) 2026-02-11 EP claimed
US-20250369916-A1 ELECTROCHEMICAL BIOSENSOR, PREPARATION METHOD, AND USE SHANGHAI UNITED IMAGING MICROELECTRONICS TECH CO LTD (CN) 2025-12-04 US claimed
EP-4656733-A1 ELECTROCHEMICAL BIOSENSOR, PREPARATION METHOD, AND USE Shanghai United Imaging Microelectronics Technology Co., Ltd. (CN) 2025-12-03 EP claimed
CN-119101214-A Cycloolefin metathesis composition and polymerization method thereof 道生天合材料科技(上海)股份有限公司 2024-12-10 CN claimed
US-20240336895-A1 METHODS FOR RAPIDLY INFILTRATING 3D SCAFFOLDS WITH CELLS SPIDERWORT INC. (CA) 2024-10-10 US claimed
WO-2024206469-A2 METHODS AND COMPOSITIONS FOR ENHANCED EXPRESSION OF EXOGENOUS CASEINS IN TRANSGENIC PLANTS Mozza Foods Inc. (US) 2024-10-03 WO claimed
EP-3470418-B1 SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IGG-BINDING PEPTIDE UNIV KAGOSHIMA (JP) 2024-07-31 EP claimed
EP-4377442-A1 METHODS FOR RAPIDLY INFILTRATING 3D SCAFFOLDS WITH CELLS Spiderwort Inc. (CA) 2024-06-05 EP claimed
US-20080125365-A1 ISOLATED COMPLEXES OF COVALENTLY CROSS-LINKED ENDOTOXIN AND MODIFIED MD-2 UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2008-05-29 US claimed
US-20070254311-A1 Covalent modification and conjugation of luciferase CARDIOGENICS INC. (CA) 2007-11-01 US claimed
WO-2007058678-A2 USES OF PEGYLATED ALBUMIN ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2007-05-24 WO claimed
EP-1133318-B1 SUPRAMOLECULAR COMPLEXES CONTAINING THERAPEUTIC AGENTS CALIFORNIA INST OF TECHN (US) 2007-03-14 EP claimed
WO-2006135740-A1 PEGYLATED HEMOGLOBIN AND ALBUMIN AND USES THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2006-12-21 WO claimed
EP-1175395-B1 METHOD OF PREPARING N,N'-DISUBSTITUTED-3,3'-DITHIODIPROPIONAMIDE AND METHOD OF PREPARING SUBSTITUTED 3-ISOTHIAZOLONE BY USING THE SAME SK CHEMICALS CO LTD (KR) 2004-09-22 EP claimed
WO-1997043645-A1 ANTIBODIES DIRECTED AGAINST DITHIOCARBAMATES MEDINOX, INC. (US) 1997-11-20 WO claimed
EP-0248621-B1 REAGENT FOR IMMUNOASSAY KABUSHIKI KAISHA TOSHIBA (JP) 1992-08-26 EP claimed
EP-0157797-A1 DETECTING AN IMMUNOLOGICAL REACTION WITH ACTIVATED RED BLOOD CELLS (ERYTHROCYTES) IMMUCOR, INC. (US) 1985-10-16 EP claimed
WO-1985001354-A1 DETECTING AN IMMUNOLOGICAL REACTION WITH ACTIVATED RED BLOOD CELLS (ERYTHROCYTES) IMMUCOR, INC. (US) 1985-03-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576163-B2 Fluorescent contrast agent with targeting function, and preparation method and use thereof CD209, FUT7, MUC1 TSHR 880/4885LMNA 2535/4885CYP1A2 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.